Dosing and administration
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼


Dosing and administration

Repatha® offers simple dosing and self-administration.1
  • One 140 mg dose every two weeks for all patients except HoFH and apheresis (QM dosing also available)*1
  • No titration needed for most ASCVD patients1
  • Store at 2–8°C1
SureClick® pre-filled pen: Instructions for use
Watch a short video about using SureClick® pre-filled pen to administer Repatha®.

One dose of Repatha® provides rapid and sustained LDL-C reductions2
One dose of Repatha® fully saturates circulating PCSK9, providing rapid LDL-C reductions that are sustained until the next dose.2

Change in LDL-C levels over time2

*The 140 mg Q2W dose is suitable for all patients except those with HoFH or on apheresis. In adults and adolescents aged 12 years and over with HoFH, the initial recommended dose is 420 mg QM. After 12 weeks of treatment, dose frequency can be up-titrated to 420 mg Q2W if a clinically meaningful response is not achieved. Patients on apheresis may initiate treatment with 420 mg Q2W to correspond with their apheresis schedule.
In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; ASCVD = Atherosclerotic cardiovascular disease; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; HoFH = Homozygous familial hypercholesterolaemia; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; Q2W = Every 2 weeks; QM = Every month; RRR = Relative risk reduction; SC = Subcutaneously
  1. Repatha® (evolocumab) Summary of Product Characteristics. Last revised: 31 March 2021.
  2. Giugliano RP, et al. Lancet. 2012;380:2007-17.
  3. Gencer B, et al. JAMA Cardiol. 2020;5(8):1-6. Main paper & Supplementary appendix.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD